1.56% -0.015

Organogenesis Holdings Inc (ORGO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Organogenesis Holdings Inc Stock (ORGO) Company Profile

Organogenesis Holdings Inc

Healthcare (1087)

781-575-0775

85 DAN ROAD, CANTON, MA

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ORGO's Discussions on Twitter

Compare ORGO vs TAK, TEVA, HLN, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ORGO Organogenesis Holdings Inc	1.585	205.88M	514.70M	2.72M	17.08M	-0.1589
TAK Takeda Pharmaceutical Co Adr	18.27	58.50B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.88	42.84B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.17	40.68B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	73.50	30.40B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	497.22	21.36B	3.17B	1.29B	1.01B	27.09

Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-06-28	Eingeleitet	Lake Street	Buy
2024-02-07	Eingeleitet	Cantor Fitzgerald	Overweight
2023-06-15	Eingeleitet	Morgan Stanley	Equal-Weight
2023-05-24	Hochstufung	BTIG Research	Neutral → Buy
2022-11-10	Herabstufung	BTIG Research	Buy → Neutral
2022-08-10	Herabstufung	Oppenheimer	Outperform → Perform
2020-01-10	Eingeleitet	SVB Leerink	Outperform
2019-08-26	Fortgesetzt	Credit Suisse	Outperform
2019-05-02	Eingeleitet	Credit Suisse	Outperform
2019-04-17	Eingeleitet	Oppenheimer	Outperform
2019-04-11	Eingeleitet	SunTrust	Buy

Alle ansehen

Organogenesis Holdings Inc Aktie (ORGO) Neueste Nachrichten

Finanzdaten der Organogenesis Holdings Inc-Aktie (ORGO)

Organogenesis Holdings Inc-Aktie (ORGO) Insiderhandel

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Driscoll Michael Joseph	Director	Mar 09 '26	Buy	2.67	10,000	26,688	225,707
NUSSDORF GLENN H	Director	Dec 16 '25	Sale	5.14	200,000	1,027,060	2,565,591

Organogenesis Holdings Inc (ORGO)

Organogenesis Holdings Inc Stock (ORGO) Company Profile

Compare ORGO vs TAK, TEVA, HLN, ZTS, UTHR

Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades

Organogenesis Holdings Inc Aktie (ORGO) Neueste Nachrichten

Organogenesis stock trades without a fresh catalyst, recent results define the picture - AD HOC NEWS

Organogenesis (ORGO) Quarter in Focus: Reported EPS Misses Expectations for the Current Session; Closing Reaction - vinanet.vn

ORGO | Organogenesis Holdings Inc. Class FinancialsRevenue Breakdown - Quiver Quantitative

Spotlighting Anixa Biosciences And 2 Other Noteworthy Penny Stocks - Sahm

Organogenesis (ORGO) Chart: Moves 3.35% Up to $1.85 on the Day; Current Setup: the Near-Term Reference Band Stretches From $1.76 to $1.94 in Latest TradingRSI Overbought Alerts - vinanet.vn

Organogenesis Holdings Inc (ORGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Organogenesis (ORGO) Q2 2026 Earnings Call Transcript - AOL.com

Oragenics: Q2 Earnings Snapshot - AOL.com

Organogenesis, lured to RI with tax credits, is bleeding money - The Business Journals

OrganiGram: Fiscal Q3 Earnings Snapshot - AOL.com

Organogenesis Holdings, Inc. Class A Revenue Breakdown – MUN:2PQ - TradingView

Organogenesis Holdings (ORGO) Holds Flat at $1.86 as Shares Consolidate Between Support and ResistanceBuffered ETF - vinanet.vn

Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution - Yahoo Finance

Organogenesis Holdings Inc (ORGO) Stock News Today - TradingKey

Organogenesis Holdings (ORGO) Is Down 21.5% After Slashing 2026 Guidance And Launching Equity Offering – Has The Bull Case Changed? - Yahoo Finance

Organogenesis (NASDAQ:ORGO) Cut to Strong Sell at Wall Street Zen - MarketBeat

Organogenesis Shares Plunge After Revenue Slump, Wider Loss and Lower Outlook - Moomoo

Truist Adjusts Price Target on Organogenesis to $2 From $3, Maintains Hold Rating - marketscreener.com

Truist Financial Has Lowered Expectations for Organogenesis (NASDAQ:ORGO) Stock Price - MarketBeat

Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Earnings call transcript: Organogenesis Q2 2026 miss sends shares lower By Investing.com - Investing.com Australia

Form 8K Organogenesis Holdings Inc For: 6 August By Investing.com - Investing.com Nigeria

Organogenesis Holdings enters at-the-market sales agreement for up to $75 million - Investing.com Nigeria

Organogenesis Holdings Inc. (ORGO) Stock Analysis: Potential 24% Upside For Investors - DirectorsTalk Interviews

Organogenesis Q2 Earnings Call Highlights - Yahoo Finance

[ORGO] Q2 2026 Earnings: Deep EPS Miss Sends Shares Down 22.8%Earnings Trend Analysis - vinanet.vn

Organogenesis earnings missed by $0.42, revenue fell short of estimates - Investing.com Canada

Earnings call transcript: Organogenesis Q2 2026 miss sends shares lower - Investing.com

Transcript : Organogenesis Holdings Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com

Organogenesis: Q2 Earnings Snapshot - Barchart.com

Organogenesis Holdings Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com

ORGO: Q2 2026 revenue plunged 58% and net loss widened sharply amid ongoing market and regulatory challenges - TradingView

Organogenesis (Nasdaq: ORGO) sets up $75M at-the-market stock sale - Stock Titan

Organogenesis Holdings Inc. Q2 2026: Revenue $42.8M, EPS $(0.77) — 10-Q Summary - tradingview.com

Organogenesis (NASDAQ: ORGO) hit by 58% sales drop and $149M first-half loss - Stock Titan

Organogenesis Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results - The Manila Times

Organogenesis Holdings reports Q2 2026 revenue $42.8M, net loss $96.3M - TradingView

Organogenesis Holdings Inc. Revises Revenue Guidance for the Second Half of the Year Ending December 31, 2026 - marketscreener.com

Organogenesis Holdings, Inc. Class A Revenue Breakdown – LS:A2PA31 - TradingView

Organogenesis reports Q2 2026 revenue drop 58% and net loss surges to $96.3M amid slow market recovery - Pluang

ORGO Q2'26 Earnings: EPS estimate is (0.35) USD - TradingView

Organogenesis Holdings Inc. expected to post a loss of 35 cents a shareEarnings Preview - TradingView

Organogenesis Holdings (ORGO) Shows Modest Gains, Trading Near Key Support ZoneETF AUM Growth - dars.gov.et

ORGO Q1 2026 Earnings: Deep EPS Miss Signals Persistent Profitability PressuresEarnings Quality Score - vinanet.vn

Organon: Q2 Earnings Snapshot - AOL.com

Organogenesis (ORGO) to Release Quarterly Earnings on Thursday - MarketBeat

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers - The Manila Times

Organogenesis Holdings Inc (ORGO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Organogenesis reports positive trial results for wound care product By Investing.com - Investing.com South Africa

Organogenesis reports positive trial results for wound care product - Investing.com

Finanzdaten der Organogenesis Holdings Inc-Aktie (ORGO)

Umsatz

Nettogewinn

Free Cashflow

ENV

Organogenesis Holdings Inc-Aktie (ORGO) Insiderhandel

Ähnlich wie ORGO